109 related articles for article (PubMed ID: 36209968)
1. IGT mediated Nanog siRNA delivery in prostate cancer cells improves chemosensitization of Epirubicin in vitro.
Gupta S; Das U; Sinha S
Bioorg Med Chem Lett; 2022 Nov; 76():129017. PubMed ID: 36209968
[TBL] [Abstract][Full Text] [Related]
2. Internal Oligoguanidinium Transporter: Mercury-Free Scalable Synthesis, Improvement of Cellular Localization, Endosomal Escape, Mitochondrial Localization, and Conjugation with Antisense Morpholino for NANOG Inhibition to Induce Chemosensitization of Taxol in MCF-7 Cells.
Kundu J; Banerjee P; Bose C; Das U; Ghosh U; Sinha S
Bioconjug Chem; 2020 Oct; 31(10):2367-2382. PubMed ID: 32986398
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 5'-Thiol Functionalized Morpholino Oligo-Nucleotide and Subsequent Conjugation with IGT to Improve Delivery and Antisense Efficacy
Ghosh U; Gupta S; Sinha S
Bioconjug Chem; 2023 Jan; 34(1):174-180. PubMed ID: 36538654
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Nanog inhibited cell migration and increased the sensitivity of colorectal cancer cells to 5-fluorouracil.
Khosravi N; Shahgoli VK; Amini M; Safaei S; Mokhtarzadeh A; Mansoori B; Derakhshani A; Baghbanzadeh A; Baradaran B
Eur J Pharmacol; 2021 Mar; 894():173871. PubMed ID: 33460610
[TBL] [Abstract][Full Text] [Related]
5. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library.
Zhao L; Pan Y; Gang Y; Wang H; Jin H; Tie J; Xia L; Zhang Y; He L; Yao L; Qiao T; Li T; Liu Z; Fan D
J Biol Chem; 2009 Sep; 284(39):26273-85. PubMed ID: 19638344
[TBL] [Abstract][Full Text] [Related]
6. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.
Li YT; Chua MJ; Kunnath AP; Chowdhury EH
Int J Nanomedicine; 2012; 7():2473-81. PubMed ID: 22701315
[TBL] [Abstract][Full Text] [Related]
7. siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin.
Alemohammad H; Motafakkerazad R; Asadzadeh Z; Farsad N; Hemmat N; Najafzadeh B; Vasefifar P; Baradaran B
Gene; 2022 May; 821():146333. PubMed ID: 35182674
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563
[TBL] [Abstract][Full Text] [Related]
9. Nanog suppression enhanced the chemosensitivity of human non-small-cell lung cancer cells to Cisplatin and inhibited cell migration.
Najafzadeh B; Motafakkerazad R; Najafi S; Amini M; Alemohammad H; Vasefifar P; Baradaran B
Pathol Res Pract; 2022 May; 233():153869. PubMed ID: 35398618
[TBL] [Abstract][Full Text] [Related]
10. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.
Dong H; Yao L; Bi W; Wang F; Song W; Lv Y
J Cancer Res Ther; 2015; 11(4):717-22. PubMed ID: 26881507
[TBL] [Abstract][Full Text] [Related]
11. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
[TBL] [Abstract][Full Text] [Related]
12. Nanog siRNA plus Cisplatin may enhance the sensitivity of chemotherapy in esophageal cancer.
Du Y; Shi L; Wang T; Liu Z; Wang Z
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1759-67. PubMed ID: 22714588
[TBL] [Abstract][Full Text] [Related]
13. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA.
Wu Z; Li X; Zeng Y; Zhuang X; Shen H; Zhu H; Liu H; Xiao H
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):177-84. PubMed ID: 21073659
[TBL] [Abstract][Full Text] [Related]
15. A novel peptide for efficient siRNA delivery in vitro and therapeutics in vivo.
Pan R; Xu W; Yuan F; Chu D; Ding Y; Chen B; Jafari M; Yuan Y; Chen P
Acta Biomater; 2015 Jul; 21():74-84. PubMed ID: 25861950
[TBL] [Abstract][Full Text] [Related]
16. Guanidinium-Functionalized Flexible Azaproline Transporter for Efficient Intracellular Delivery of Proapoptotic Peptide and PDL1 Antisense Morpholino Oligo in Human Carcinoma Cells
Gupta A; Gupta S; Das U; Sinha S
Bioconjug Chem; 2022 May; 33(5):907-917. PubMed ID: 35486710
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers.
Zheng W; Yin T; Chen Q; Qin X; Huang X; Zhao S; Xu T; Chen L; Liu J
Acta Biomater; 2016 Feb; 31():197-210. PubMed ID: 26612416
[TBL] [Abstract][Full Text] [Related]
18. [RNAi-mediated gene silencing of livin synergistic with epirubicin enhance apoptosis of human breast cancer cells].
Liang CY; Ma P; Liu XL
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1703-6. PubMed ID: 19024543
[TBL] [Abstract][Full Text] [Related]
19. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
[TBL] [Abstract][Full Text] [Related]
20. [siRNA against survivin coupling with epirubicin enhances to induce breast cancer cell MCF-7 to apoptosis].
Guan HT; Xue XH; Wang XJ; Li A; Qin ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):221-5. PubMed ID: 16608080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
